The frequency of metabolic syndrome in psychiatric patients using antidepressant medications/Antidepresan kullanan psikiyatrik hastalarda metabolik sendrom sikligi

Objective: There are limited studies investigating the metabolic syndrome (MS) in patients using antidepressants. This study examines and compares the prevalence of MS and related factors in psychiatric patients taking various antidepressants at an outpatient clinic. Methods: The study comprised a total of 70 patients using fluoxetine, paroxetine, sertralin, citalopram, essitalopram, clomipramine and venlafaxine aged 18- 60 years with depressive and anxiety disorder. MS rates of patients (according to National Cholesterol Education Program-Adult Treatment Panel III-(NCEP III)) who met the study criteria were obtained. Results: In our study metabolic syndrome frequency was 32.8% in total patient groups according to NCEP-III criteria. The higher metabolic syndrome frequency was found in drug groups such as clomipramine, paroxetine and venlafaxine groups. The safest drug for metabolic syndrome was fluoxetine as seen in its relevant group. Conclusion: Conventional antidepressants may cause metabolic syndrome which is important for mortality, morbidity and quality of life of psychiatric patients. Keywords: metabolic syndrome, venlafaxine, clomipramine, fluoxetine, depressive disorder, anxiety disorder Amac: Antidepresan kullanan hastalarda metabolik sendrom (MS) varligini arastiran calisma sayisi kisitlidir. Bu calisma ile poliklinige basvuran ve cesitli antidepresan kullanan psikiyatrik hastalarda MS ve iliskili faktorlerin oranlarini arastirmak ve karsilastirmak amaclanmistir. Yontem: Calisma fluoksetin, paroksetin, sertralin, citalopram, essitalopram, klomipramin, venlafaksin kullanan 18-60 yas arasi depresif ve anksiyete bozukluguna sahip 70 hastadan olusmustur. Calisma olcutlerine uyan hastalarin aclik kan sekerleri, kan trigliserit ve kolesterol duzeyleri, ortalama kan basinci, vucut kitle indeksi, bel cevresi ve Ulusal Kolesterol Egitim Programi - Eriskin Tedavi Paneli III'e gore (NCEP-III) MS oranlari tespit edildi. Sonuc: NCEP-III'e gore tum hastalardaki MS sikligi %32,8 idi. En yuksek metabolik sendrom oranlari klomipramin, paroksetin ve venlafaksin gruplarinda saptandi. Fluoksetin grubu metabolik sendrom acisindan en guvenli ilac olarak saptandi. Tartisma: Klasik antidepresanlar metabolik senrom oranlari ni artirmaktadir ve bu da psikiyatrik hastalarin mortalite, morbidite ve yasam kalitesini etkilemesi acisindan oldukca onemlidir. Anahtar sozcukler: Metabolik sendrom, SSRI, venlafaksin, klomipramin, fluoksetin, depresif bozukluk, anksiyete bozuklugu